By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...

Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

The sales of Pfizer’s Comirnaty shots sank 25% after the U.S. government narrowed recommendations of who needs the jab ...

Despite hopes raised by Pfizer's COVID-19 vaccine, it will take huge efforts for India to defeat the coronavirus, with its ...

The European Union reached a deal with Pfizer and BioNTech for 300 million additional doses of their COVID-19 vaccine, the ...

Drugmaker Pfizer said Friday that as government contracts come to an end, possibly by early next year, its COVID-19 vaccine will be sold for $110 to $130 per dose. This price model comes down to ...

Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as ...

A new study shows children and young people face long-lasting and higher risks of rare heart and inflammatory complications ...